Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Dec 1 2009

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced that results from preclinical and clinical studies of two, novel blood forming agents, ACE-011 and ACE-536, will be presented at the 51^st Annual Meeting of the American Society of Hematology at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Results of ACE-011 studies will be presented at the following times and locations:

• “ACE-011, A SOLUBLE ACTIVIN RECEPTOR TYPE IIA IGG-FC FUSION PROTEIN, INCREASES HEMOGLOBIN AND IMPROVES BONE LESIONS IN MULTIPLE MYELOMA PATIENTS RECEIVING MYELOSUPPRESSIVE CHEMOTHERAPY: PRELIMINARY ANALYSIS” (Oral Presentation); Hall F, December 7th, 5:30 PM
• “RAP-011, A SOLUBLE ACTIVIN RECEPTOR TYPE IIA MURINE IGG-FC FUSION PROTEIN, PREVENTS CHEMOTHERAPY INDUCED ANEMIA” (Oral Presentation); Rooms 220-222, December 6th, 5:30 PM
• “MOLECULAR SEQUELAE OF ACTIVIN A-DEPENDENT OSTEOBLAST INHIBITION OF MYELOMA” (Poster Board I-811); Hall E, December 5th 5:30 PM

Results of ACE-536 studies will be presented at the following times and locations:

• “ACE-536, A NOVEL, GDF-TRAP, PROMOTES RAPID INCREASE OF RED BLOOD CELLS IN VIVO IN AN EPO-INDEPENDENT MANNER” (Poster Board II - 482); Hall E, December 6th, 6:00 PM
• “ACE-536, A NOVEL, GDF-TRAP, INCREASES HEMOGLOBIN, HEMATOCRIT, AND RED BLOOD CELLS IN RATS AND MONKEYS” (Poster Board III – 540); Hall E, December 7th, 6:00 PM
• “ADMINISTRATION OF A NOVEL GDF-TRAP PREVENTS ANEMIA INDUCED BY RENAL INSUFFICIENCY AND AUGMENTS RECOVERY FROM BLOOD LOSS” (Poster Board III – 973); Hall E, December 7th, 6:00 PM

SOURCE Acceleron Pharma, Inc.,